Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier

Daniel Kim Views  

Shutterstock
Shutterstock

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s treatment for myasthenia gravis.

About 100,000 people in the U.S. suffer from myasthenia gravis, an autoimmune condition that weakens the skeletal muscles of the mouth, throat, eyes, and limbs.

Although myasthenia gravis comes in various forms, Johnson & Johnson claims that Imaavy works for over 90% of patients.

In 2020, Johnson & Johnson paid $6.5 billion to acquire Momenta, which included Imaavy. A 1,200 mg vial usually is priced at $12,480.

According to the findings of a 24-week late-stage clinical trial, Imaavy considerably improved the ability of patients with myasthenia gravis to carry out everyday tasks like speaking, breathing, and chewing. This FDA approval was based on those findings.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Why Your Eyelid Keeps Twitching—and When to Worry
  • Silent Spreaders: How Measles Can Infect Before Symptoms Appear
  • Eat More Eggplant—It’s Good for Your Blood and Your Heart
  • Want to Burn More Fat? Try a 30-Second Cold Shower, Experts Say
  • Bats, Fruit, and a Deadly Virus—Why Korea’s Health Officials Are on High Alert
  • Why You Crave Junk Food When You’re Sad—And What to Eat Instead

You May Also Like

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Must-Reads

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Share it on...